Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes

Molecular Cytogenetics

Volumn 3, Issue 1, 2010, Pages

  Slovak, Marilyn L ^a,c   Smith, David D ^a   Bedell, Victoria ^a   Hsu, Ya Hsuan ^a   O'Donnell, Margaret ^a   Forman, Stephen J ^a   Gaal, Karl ^a   McDaniel, Lisa ^b   Schultz, Roger ^b   Ballif, Blake C ^b   Shaffer, Lisa G ^b  

^a Department of Cytogenetics ^*  (United States)

^b Signature Genomics   (United States)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR RUNX1;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CLINICAL ARTICLE; CLONAL VARIATION; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; KARYOTYPE; MALE; MICROARRAY ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL;

BACTERIA (MICROORGANISMS);

EID: 78149424920     PISSN: None     EISSN: 17558166     Source Type: Journal    
DOI: 10.1186/1755-8166-3-23     Document Type: Article

References (48)

1. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. JW Vardiman J Thiele DA Arber RD Brunning MJ Borowitz A Porwit NL Harris MM Le Beau E Hellstrom-Lindberg A Tefferi CD Bloomfield, Blood 2009 114 937 951 10.1182/blood-2009-03-209262 19357394
2. Myelodysplastic syndromes: incidence and survival in the United States. X Ma M Does A Raza ST Mayne, Cancer 2007 109 1536 1542 10.1002/cncr.22570 17345612 (Pubitemid 46595689)
3. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. MA Sekeres WM Schoonen H Kantarjian A List J Fryzek R Paquette JP Maciejewski, J Natl Cancer Inst 2008 100 1542 1551 10.1093/jnci/djn349 18957672
4. Cancer in the oldest old: making better treatment decisions. LC Hanson HB Muss, J Clin Oncol 28 1975 1976 10.1200/JCO.2009.27.6022 20308651
5. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. LP Gondek AJ Dunbar H Szpurka MA McDevitt JP Maciejewski, PLoS One 2007 2 1225 10.1371/journal.pone. 0001225 18030353
6. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. LP Gondek R Tiu CL O'Keefe MA Sekeres KS Theil JP Maciejewski, Blood 2008 111 1534 1542 10.1182/blood-2007-05-092304 17954704
7. Whole genome scanning as a cytogenetic tool in hematologic malignancies. JP Maciejewski GJ Mufti, Blood 2008 112 965 974 10.1182/blood-2008-02-130435 18505780
8. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. A Mohamedali J Gaken NA Twine W Ingram N Westwood NC Lea J Hayden N Donaldson C Aul N Gattermann A Giagounidis U Germing AF List GJ Mufti, Blood 2007 110 3365 3373 10.1182/blood-2007-03-079673 17634407
9. International scoring system for evaluating prognosis in myelodysplastic syndromes. P Greenberg C Cox MM LeBeau P Fenaux P Morel G Sanz M Sanz T Vallespi T Hamblin D Oscier K Ohyashiki K Toyama C Aul G Mufti J Bennett, Blood 1997 89 2079 2088 9058730
10. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. D Haase U Germing J Schanz M Pfeilstocker T Nosslinger B Hildebrandt A Kundgen M Lubbert R Kunzmann AA Giagounidis C Aul L Trumper O Krieger R Stauder TH Muller F Wimazal P Valent C Fonatsch C Steidl, Blood 2007 110 4385 4395 10.1182/blood-2007-03-082404 17726160
11. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. A List G Dewald J Bennett A Giagounidis A Raza E Feldman B Powell P Greenberg D Thomas R Stone C Reeder K Wride J Patin M Schmidt J Zeldis R Knight, N Engl J Med 2006 355 1456 1465 10.1056/NEJMoa061292 17021321
12. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. AA Giagounidis U Germing C Strupp B Hildebrandt M Heinsch C Aul, Ann Hematol 2005 84 569 571 10.1007/s00277-005-1054-0 15891887
13. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. M Lubbert P Wijermans R Kunzmann G Verhoef A Bosly C Ravoet M Andre A Ferrant, Br J Haematol 2001 114 349 357 10.1046/j.1365-2141.2001.02933.x 11529854
14. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. K Raj A John A Ho C Chronis S Khan J Samuel S Pomplun NS Thomas GJ Mufti, Leukemia 2007 21 1937 1944 10.1038/sj.leu.2404796 17611569
15. Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy. D Nowak F Nolte M Mossner V Nowak CD Baldus O Hopfer S Noll E Thiel F Wagner WK Hofmann, Exp Hematol 2009 37 215 224 10.1016/j.exphem.2008. 10.012 19135900
16. High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. K Paulsson M Heidenblad B Strombeck J Staaf G Jonsson A Borg T Fioretos B Johansson, Leukemia 2006 20 840 846 10.1038/sj.leu.2404145 16498392
17. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. C Evers M Beier A Poelitz B Hildebrandt K Servan M Drechsler U Germing HD Royer B Royer-Pokora, Genes Chromosomes Cancer 2007 46 1119 1128 10.1002/gcc.20498 17823930
18. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. DT Starczynowski S Vercauteren A Telenius S Sung K Tohyama A Brooks-Wilson JJ Spinelli CJ Eaves AC Eaves DE Horsman WL Lam A Karsan, Blood 2008 112 3412 3424 10.1182/blood-2007-11-122028 18663149
19. Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. T Akagi S Ogawa M Dugas N Kawamata G Yamamoto Y Nannya M Sanada CW Miller A Yung S Schnittger T Haferlach C Haferlach HP Koeffler, Haematologica 2009 94 213 223 10.3324/haematol.13024 19144660
20. Proposals for the classification of the myelodysplastic syndromes. JM Bennett D Catovsky MT Daniel G Flandrin DA Galton HR Gralnick C Sultan, Br J Haematol 1982 51 189 199 6952920
21. The Myelodysplastic Syndromes/Neoplasms. World Health Organization of Tumors of Haematopoietic and Lymphoid Tissues Lyon: IARC, Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, 2008 87 104
22. Stimulation of proliferation of human myeloid leukemia cells in culture: applications for cytogenetic analysis. J Michaeli I Lerer EA Rachmilewitz E Fibach, Blood 1986 68 790 793 3461854
23. ISCN (2009): An International System for Human Cytogenetic Nomenclature. LG Shaffer ML Slovak LJ Campbell (Eds), Basel: S. Karger 2009
24. An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies. D Bobadilla EL Enriquez G Alvarez P Gaytan D Smith ML Slovak, Br J Haematol 2007 136 806 813 10.1111/j.1365-2141.2007.06505.x 17341266
25. Expanding the clinical phenotype of the 3q29 microdeletion syndrome and characterization of the reciprocal microduplication. BC Ballif A Theisen J Coppinger GC Gowans JH Hersh S Madan-Khetarpal KR Schmidt R Tervo LF Escobar CA Friedrich M McDonald L Campbell JE Ming EH Zackai BA Bejjani LG Shaffer, Mol Cytogenet 2008 1 8 10.1186/1755-8166-1-8 18471269
26. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization. ML Slovak V Bedell K Pagel KL Chang D Smith G Somlo, Cancer Genet Cytogenet 2005 158 99 109 10.1016/j.cancergencyto.2005.01.006 15796956
27. Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. JP Maciejewski RV Tiu C O'Keefe, Br J Haematol 2009 146 479 488 10.1111/j.1365-2141.2009.07757.x 19563474
28. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. L Wang C Fidler N Nadig A Giagounidis MG Della Porta L Malcovati S Killick N Gattermann C Aul J Boultwood JS Wainscoat, Haematologica 2008 93 994 1000 10.3324/haematol.12603 18508791
29. Haploinsufficiency of RPS14 in 5q-syndrome is associated with deregulation of ribosomal- and translation-related genes. A Pellagatti E Hellstrom-Lindberg A Giagounidis J Perry L Malcovati MG Della Porta M Jadersten S Killick C Fidler M Cazzola JS Wainscoat J Boultwood, Br J Haematol 2008 142 57 64 10.1111/j.1365-2141.2008.07178.x 18477045
30. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. BL Ebert J Pretz J Bosco CY Chang P Tamayo N Galili A Raza DE Root E Attar SR Ellis TR Golub, Nature 2008 451 335 339 10.1038/nature06494 18202658
31. Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q-syndrome. A Valencia J Cervera E Such MA Sanz GF Sanz, Blood 2008 112 918 10.1182/blood-2008-05-159707 18650472
32. Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes. B Stewart M Verdugo KA Guthrie F Appelbaum HJ Deeg, Br J Haematol 2003 123 879 885 10.1046/j.1365-2141.2003. 04713.x 14632779
33. Deletions of CDKN1B and ETV6 in acute myeloid leukemia and myelodysplastic syndromes without cytogenetic evidence of 12p abnormalities. P Andreasson B Johansson K Arheden R Billstrom F Mitelman M Hoglund, Genes Chromosomes Cancer 1997 19 77 83 10.1002/(SICI)1098-2264(199706)19:2<77::AID- GCC2>3.0.CO;2-X 9171997
34. Granulocyte-macrophage colony-stimulating factor abrogates transforming growth factor-beta 1-mediated cell cycle arrest by up-regulating cyclin D2/Cdk6. F Ohtsuki M Yamamoto T Nakagawa T Tanizawa H Wada, Br J Haematol 1997 98 520 527 10.1046/j.1365-2141.1997.2643079.x 9332304
35. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS. ML Slovak M O'Donnell DD Smith K Gaal, Cancer Genet Cytogenet 2009 193 78 85 10.1016/j.cancergencyto.2009.04.013 19665067
36. Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms. M Sanada N Uike K Ohyashiki K Ozawa W Lili A Hangaishi Y Kanda S Chiba M Kurokawa M Omine K Mitani S Ogawa, Leukemia 2007 21 992 997 17315020
37. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. J Pedersen-Bjergaard MK Andersen MT Andersen DH Christiansen, Leukemia 2008 22 240 248 10.1038/sj.leu.2405078 18200041
38. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. H Niimi H Harada Y Harada Y Ding J Imagawa T Inaba T Kyo A Kimura, Leukemia 2006 20 635 644 10.1038/sj.leu.2404136 16467864
39. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. V Gelsi-Boyer V Trouplin J Adelaide N Aceto V Remy S Pinson C Houdayer C Arnoulet D Sainty M Bentires-Alj S Olschwang N Vey MJ Mozziconacci D Birnbaum M Chaffanet, BMC Cancer 2008 8 299 10.1186/1471-2407-8- 299 18925961
40. NF1 Inactivation in Adult Acute Myelogenous Leukemia. B Parkin P Ouillette Y Wang Y Liu W Wright D Roulston A Purkayastha A Dressel J Karp P Bockenstedt A Al-Zoubi M Talpaz L Kujawski K Shedden S Shakhan C Li H Erba SN Malek, Clin Cancer Res 2010 16 4135 4147 10.1158/1078-0432.CCR-09-2639 20505189
41. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. S Lugthart E van Drunen Y van Norden A van Hoven CA Erpelinck PJ Valk HB Beverloo B Lowenberg R Delwel, Blood 2008 111 4329 4337 10.1182/blood-2007-10-119230 18272813
42. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. S Groschel S Lugthart RF Schlenk PJ Valk K Eiwen C Goudswaard WJ van Putten S Kayser LF Verdonck M Lubbert GJ Ossenkoppele U Germing I Schmidt-Wolf B Schlegelberger J Krauter A Ganser H Dohner B Lowenberg K Dohner R Delwel, J Clin Oncol 2010 28 2101 2107 10.1200/JCO.2009.26.0646 20308656
43. transCGH: rapid identification and high-resolution mapping of balanced IgH translocations in archival DNA using custom oligonucleotide arrays. HA Greisman HS Yi NG Hoffman, American Society of Hematology Annual Meeting. Atlanta, GA 2007
44. Multiple forms of atypical rearrangements generating supernumerary derivative chromosome 15. NJ Wang AS Parokonny KN Thatcher J Driscoll BM Malone N Dorrani M Sigman JM LaSalle NC Schanen, BMC Genet 2008 9 2 10.1186/1471-2156-9-2 18177502
45. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. V Gelsi-Boyer V Trouplin J Adelaide J Bonansea N Cervera N Carbuccia A Lagarde T Prebet M Nezri D Sainty S Olschwang L Xerri M Chaffanet MJ Mozziconacci N Vey D Birnbaum, Br J Haematol 2009 145 788 800 10.1111/j.1365-2141.2009.07697.x 19388938
46. Mutation in TET2 in myeloid cancers. F Delhommeau S Dupont V Della Valle C James S Trannoy A Masse O Kosmider JP Le Couedic F Robert A Alberdi Y Lecluse I Plo FJ Dreyfus C Marzac N Casadevall C Lacombe SP Romana P Dessen J Soulier F Viguie M Fontenay W Vainchenker OA Bernard, N Engl J Med 2009 360 2289 2301 10.1056/NEJMoa0810069 19474426
47. Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. DP Steensma JD Neiger JC Porcher JJ Keats PL Bergsagel TR Dennis RA Knudson RB Jenkins R Santana-Davila R Kumar RP Ketterling, Cancer Res 2009 69 7518 7523 10.1158/0008-5472.CAN-09-1428 19773435
48. AJ Dunbar LP Gondek CL O'Keefe H Makishima MS Rataul H Szpurka MA Sekeres XF Wang MA McDevitt JP Maciejewski, 250 K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008 68 10349 10357 10.1158/0008-5472.CAN-08-2754 19074904